Seeking Alpha Usana operates similarly to Herbalife where commodity-like products are sold at premiums through a heavy emphasis on recruiting rather than traditional means of advertising and R&D. ... New rules by the FTC could would spillover to China . ... a six ... and more »
DigitalJournal.com Then what comes the next are Chinese patent medicine and traditional Chinese medicinal materials, which occupied 16.8% and 4.5%, respectively, of total revenue. In terms of distribution channels, the proportion of China's drug retail terminal and ... and more »
Proactive Investors UK “At that point we may then have to go on a waiting list or be prescribed drugs for life. That's why ... Possibly its most exciting product is a food supplement capsule form of Benecol, the brand of spreads and yoghurt shots that contain a unique ...
Financial Times The three cases are all very different but together they create the impression of an industry in flux as it searches for a new growth model after a decade-long wilderness of patent expiries and misfiring development pipelines. “The plates are ... Like ...
Insurance News Net (press release) Then what comes the next are Chinese patent medicine and traditional Chinese medicinal materials, which occupied 16.8% and 4.5%, respectively, of total revenue. In terms of distribution channels, the proportion of China's ... But due to policy ... and more »
PR Newswire UK (press release) Then what comes the next are Chinese patent medicine and traditional Chinese medicinal materials, which occupied 16.8% and 4.5%, respectively, of total revenue. In terms of distribution channels, the proportion of China's ... But due to policy ... and more »
Wall Street Journal Restated for this effect, sales were up 8.5%, driven by strong volume growth in China (notably Decapeptyl(R) and Smecta(R) ), the Middle East and Brazil where Dysport(R) sales recorded good performance in aesthetics and therapeutics. ... difficulties ... and more »
Insurance News Net (press release) Then what comes the next are Chinese patent medicine and traditional Chinese medicinal materials, which occupied 16.8 percent and 4.5 percent, respectively, of total revenue. In terms of distribution channels, the proportion of ... But due to policy ...
SYS-CON Media (press release) Competition pattern of olmesartan medoxomil manufacturers from Menet indicates that olmesartan medoxomil produced by Beijing Winsunny Pharmaceutical Co., Ltd. could not go on the market until patent ZL.97126347.7 expired in 2011. As a result ... Market ... and more »
SYS-CON Media (press release) By formulating amlexanox in its proprietary mucoadhesive polymer hydrogel delivery system, Access has a patented and protectable formulation of this interesting pharmaceutical active. "Leveraging upon our success with ... MuGard® was launched in 2010 ...
